Glenn Sblendorio Acquires Shares of 4D Molecular Therapeutics

Glenn Sblendorio, a key figure at 4D Molecular Therapeutics, Inc. (NasdaqGS: FDMT), purchased 50,000 shares of the company on June 17, 2026. The transaction was not part of a pre-arranged trading plan.

Insider Buying and Selling at 4D Molecular Therapeutics, Inc.

Several insiders, including Glenn Sblendorio, made significant purchases of 4D Molecular Therapeutics stock on June 17, 2026. Each insider, except John Milligan who acquired 75,000 shares, bought 50,000 shares. These transactions were not under Rule 10b5-1 plans.

Other Institutional Activity in 4D Molecular Therapeutics

Recent institutional activity shows mixed moves among major holders. Janus Henderson Group PLC increased its stake by 611,276 shares, ending with 5,247,151 shares valued at approximately $48.9 million. RA Capital Management, L.P. reduced its position by 603,432 shares, now holding 5,049,779 shares worth about $47 million. Goldman Sachs Group Inc. trimmed its holdings by 97,467 shares, leaving it with 4,205,438 shares valued at $39.2 million. Meanwhile, BlackRock, Inc. added 80,427 shares, bringing its total to 4,145,303 shares, valued at $38.6 million.

4D Molecular Therapeutics Stock Snapshot

Shares of 4D Molecular Therapeutics, Inc. (NasdaqGS: FDMT) traded near $9.66. The company has a market capitalization of $504.9 million. It is not currently profitable, hence no meaningful P/E ratio. The stock has a beta of 2.756, indicating higher volatility compared to the market. Over the past 52 weeks, the stock's low was $3.68 and its high was $12.34. The 50-day moving average is $9.43, and the 200-day moving average is $9.24. The company maintains a strong liquidity position with a current ratio of 9.339 and a quick ratio of 9.006.

Recent Earnings

4D Molecular Therapeutics reported revenue of $88.2 million, showing a growth of over 216%. Despite this, the company posted a negative net margin of -182.3% and a return on equity of -34.9%. The next earnings report is scheduled for August 10, 2026.

Analysts Set New Price Targets

On March 30, 2026, Jefferies assumed coverage with a buy rating and set a price target of $21. HC Wainwright & Co. reiterated its buy rating with a $36 target on March 20, 2026. RBC Capital maintained its buy rating with a $35 target on March 19, 2026. The consensus among nine analysts is a buy rating, with an average target price of $28.22.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, Inc. is a biotechnology company headquartered in Emeryville, California. It focuses on developing adeno-associated virus vectors for gene therapy, using its proprietary platform, Therapeutic Vector Evolution. The company is working on several products, including 4D-150 for retinal diseases and 4D-710 for cystic fibrosis. Founded in 2013, it collaborates with Otsuka Pharmaceutical Co., Ltd.

Bottom Line

Glenn Sblendorio's recent purchase of 4D Molecular Therapeutics shares highlights ongoing insider interest in the company. Investors often track insider buying as a potential signal of confidence in the company's future. As a biotechnology firm, 4D Molecular Therapeutics continues to develop innovative treatments, and the stock remains under close watch by analysts and investors alike. Remember, insider transactions are disclosed after the fact and may not reflect the current position.